Please use this identifier to cite or link to this item:
|Title:||Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI.|
|Authors:||Wight, Joel C;Chong, Geoffrey;Grigg, Andrew P;Hawkes, Eliza A|
|Affiliation:||Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia|
University of Melbourne, Melbourne, Australia
Eastern Health, Box Hill, Australia
|Citation:||Blood reviews 2018; 32(5): 400-415|
|Abstract:||Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes. Despite the majority of patients being cured with combination chemoimmunotherapy, up to 30% eventually succumb to the disease. Until recently, baseline prognostic assessment has centred on the International Prognostic Index (IPI), although this index is yet to impact strongly on treatment choice. Molecular features such as cell of origin, MYC and BCL-2 genetic alterations and protein overexpression were identified over a decade ago, yet their prognostic value is still not fully elucidated. Adding complexity are the plethora of new clinical, biological and molecular prognostic markers described in the recent literature, most of which lack independent validation, likely act as surrogate markers for those already in common use and have yet to substantially impact on therapeutic decision making. This review comprehensively assesses the value of individual prognostic markers in the clinical setting and their potential to predict response to novel agents, and ways to optimise their use in future research.|
|Subjects:||Cell of origin|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.